section name header

Pronunciation

a-DEF-oh-veer

Classifications

Therapeutic Classification: antivirals

Pharmacologic Classification: nucleotides

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Rapidly converted from prodrug form (adefovir dipivoxil) to adefovir following oral administration; 59% bioavailable.

Distribution: 0.35–0.39 L/kg.

Metabolism/Excretion: Elimination is primarily renal as unchanged drug.

Half-life: 7.5 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknown1–4 hrunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: pruritus, rash.

F and E: LACTIC ACIDOSIS.

GI: liver enzymes, abdominal pain, diarrhea, dyspepsia, flatulence, HEPATOMEGALY WITH STEATOSIS, nausea, vomiting.

GU: hematuria, nephrotoxicity.

MS: weakness.

Neuro: headache.

Resp: cough, pharyngitis, sinusitis.
Misc: HIV resistance, fever.

Interactions

Drug-Drug:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Hepsera